HealthTree

Foundation

Sign In / Join

favorite Donate

close

person Sign In / Create Account

Conferences

Our Conferences articles contain the latest coverage of medical advancements from recent academic conferences.

Headlines All Categories Treatment Advances Navigating Your Health Core Education Patient Stories HealthTree Research Conferences Clinical Trials HealthTree Programs HealthTree Press

Recent Articles

Assessing Racial and Ethnic Disparities and Outcomes in Myelofibrosis

April 04, 2025

Learn about myelofibrosis outcomes, risk factors, treatment disparities, and survival rates from the Chicagoland study findings.

Is Fedratinib Safe for Myelofibrosis Patients with Low Platelets?

March 05, 2025

Is the JAK2 inhibitor fedratinib a safe second treatment for myelofibrosis patients with low platelet levels?

Myelofibrosis Research Highlights from the 2024 ASH Conference

December 16, 2024

Read about the myelofibrosis research highlights from the 2024 ASH conference.

Effects of Eating Fiber, Plant-Based Diet, Keto Diet, and Smoking on Certain Blood Cancers

December 10, 2024

Read research highlights from the ASH 2024 conference how certain lifestyle choices affect blood cancers.

The Best of ASH 2024

December 09, 2024

Discover the board's selection of best abstracts at the 66th annual ASH conference.

ASH 2024 Begins! A Symposium on MF Care: And Why It Matters to You

December 06, 2024

Top myelofibrosis specialists gathered to discuss mastering the art of MF care. Case studies shaped the discussion. Learn more!

What is the ASH Conference?

December 02, 2024

The American Society of Hematology's annual conference is a significant event for the blood cancer community, including those involved in MF research.

Testing a New Combination Therapy for Myelofibrosis Treatment

August 12, 2024

Navitoclax with Ruxolitinib in Phase III trial shows promise for myelofibrosis, significantly reducing spleen size and improving patient symptoms.

ASCO 2024: The MANIFEST-2 Study for Myelofibrosis

June 12, 2024

Discover the latest in myelofibrosis: Phase 3 study shows promising results for Pelabresib + Ruxolitinib, reducing spleen size and improving symptoms.

What is the ASCO Conference?

May 27, 2024

The American Society of Clinical Oncology holds a yearly conference in June to allow researchers and doctors in the cancer community an opportunity to share…

Conferences

Recent Articles

Assessing Racial and Ethnic Disparities and Outcomes in Myelofibrosis

Is Fedratinib Safe for Myelofibrosis Patients with Low Platelets?

Myelofibrosis Research Highlights from the 2024 ASH Conference